Abstract 158P
Background
The contribution of cross-presenting XCR1+ dendritic cells (DCs) and SIRPα+ DCs in maintaining T cell function in chronic infection has been previously described by our group, but their impact in cancer immunotherapy remains unexplored. We report results from the prespecified translational analysis in VENEZOLUNG trial and preliminary efficacy and safety data.
Methods
VENEZOLUNG is an open-label, phase 1b/2 trial evaluating the safety and efficacy of autologous tumor lysate-pulsed DC product combined with atezolizumab as maintenance therapy in extensive stage small cell lung cancer (ES-SCLC). After standard induction, patients received up to six doses of mature DCs intradermally and atezolizumab 1200 mg iv every three weeks. The dynamic interplay between the DC populations and exhausted CD8+ T cell subsets was analyzed in patient blood samples by flow cytometry to assess markers of T cell exhaustion, effector regulatory T cells, gamma delta T cells, and XCR1+cDC1, exploring correlations with clinical outcomes.
Results
20 patients enrolled, mostly PD-L1 negative (75%) and SCLC-A subtype (58%). Seventeen patients completed DC vaccination (median doses 3, range 1-6). Treatment-related adverse events (TRAEs) occurred in 80% of patients, most grade 1-2. Grade 3-4 TRAEs were chemotherapy related: neutropenia (25%), anemia (15%), thrombocytopenia (10%) and lymphopenia (5%). DC vaccination side effects were grade 1-2 injection site irritation (15%). Overall response was 94%. After a median follow up of 17.4 months (m), median progression free survival was 4.7 m (95% CI, 4.2 to 5.8) and overall survival (OS) 11.6 m (95%CI 6.3, 17.9). PBMCs pre- and post-treatment from 10 patients showed those with expansion of circulating XCR1+ DC (n=6) had a parallel increase in CXCR5+PD-1+ follicular helper CD8 T cells and a median OS of 26 m (95% CI, 6.8, NA) vs 6.3 m (95% CI, 5-12.1) in patients without significant XCR1+ DC expansion (p=0.035). Decrease of Tpex (CXCR5+ PD1+ non-naive CD8+ T cells), cDC1s, cDC2scorrelated with higher risk of death (p-value <0.05).
Conclusions
The role of XCR1+ DCs could be crucial for checkpoint inhibitor-based therapy.
Clinical trial identification
NCT04487756.
Legal entity responsible for the study
Institut Oncologico Dr Rosell (IOR).
Funding
Roche.
Disclosure
M. Gonzalez Cao: Non-Financial Interests, Institutional, Sponsor/Funding: Roche, Regeneron, Astra zeneca, Novartis. All other authors have declared no conflicts of interest.
Resources from the same session
124P - AI-designed cancer vaccines: Antigens from the dark genome are promising cancer vaccine targets
Presenter: Daniela Kleine-Kohlbrecher
Session: Poster Display session
125P - Enhancing the efficacy of neoantigen tumor vaccines in melanoma treatment through different administration times
Presenter: Kai Xiao
Session: Poster Display session
126P - Combination of oncolytic viruses, radiation therapy, and immune checkpoint inhibitor treatment in a breast cancer model
Presenter: Olga Bezborodova
Session: Poster Display session
127P - Combining chemotherapy and checkpoint inhibitors with an engineered oncolytic adenovirus encoding a human vIL-2 cytokine to treat pancreatic ductal adenocarcinoma
Presenter: Nea Ojala
Session: Poster Display session
128P - Non-coding DNA lipid nanoparticles elicit antitumor immune responses and synergize with anti-PDL1 antibodies in mouse models of hepatocellular carcinoma
Presenter: Alba Rodriguez Garcia
Session: Poster Display session
129P - Computational approaches for enhancing the efficacy of cancer immunotherapy
Presenter: Byungho Lim
Session: Poster Display session
130P - Neoadjuvant treatment with a bispecific antibody cadonilimab in dMMR/MSI-H locally advanced colorectal cancer: Preliminary results from a phase II trial
Presenter: Caifeng Gong
Session: Poster Display session
131P - The efficacy and safety of cadonilimab with or without trastuzumab in combination with SOX as first-line (1L) treatment for advanced gastric (G) or gastroesophageal Junction adenocarcinoma (GEJA)
Presenter: Wenhui Yang
Session: Poster Display session
132P - An open-label, prospective phase II study of cadonilimab in combination with neoadjuvant chemotherapy for patients diagnosed with advanced ovarian cancer (AK104-IIT-003)
Presenter: Jie Tang
Session: Poster Display session